Schizophrenia is a common and severely disabling mental disease, which has the characteristics of recurrent attacks, diverse clinical manifestations, complex pathogenesis, and can be accompanied by a variety of endocrine diseases. Polycystic ovary syndrome (PCOS) is an endocrine disorder disease characterized by androgen excess, ovulation dysfunction and polycystic ovary morphology. This article summarizes and briefly describes the related literature on neurobiochemistry, mainly including 5-hydroxytryptamine(5-HT), norepinephrine (NE), dopamine (DA), β-Endorphin(β-EP), acetylcholine(Ach)γ-Research progress on the changes of aminobutyric acid(GABA), glutamic acid and other neurotransmitters and receptors between schizophrenia and polycystic ovary syndrome. It can be concluded that schizophrenia and polycystic ovary syndrome are closely related in neurobiochemistry, and multiple neurotransmitters are involved in the occurrence and development of both. The changes of neurotransmitters directly or indirectly affect the development and remission of diseases, which provides a new treatment idea for the treatment of two diseases, comorbidity or prevention.

Xuemei Gao, Feihu Liu. Advances in Neurobiochemical Studies of Schizophrenia and Polycystic Ovary Syndrome. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 8: 22-27. https://doi.org/10.25236/IJFM.2024.060804.

[1] GOFF D C. The Pharmacologic Treatment of Schizophrenia—2021[J/OL]. JAMA, 2021, 325(2): 175-176. 

[2] CORRELL C U, SOLMI M, CROATTO G, et al. Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors[J/OL]. World Psychiatry, 2022, 21(2): 248-271. 

[3] MCCUTCHEON R A, REIS MARQUES T, HOWES O D. Schizophrenia—An Overview[J/OL]. JAMA Psychiatry, 2020, 77(2): 201. 

[4] Anthony W.Zoghbi, Ryan S. Dhindsa, Terry E.Goldberg, et al. High-impact rare genetic variants in severe schizophrenia[J/OL]. Proceedings of the National Academy of Sciences, 2021, 118(51): e2112560118.

[5] LEGGE S E, SANTORO M L, PERIYASAMY S, et al. Genetic architecture of schizophrenia: a review of major advancements[J/OL]. Psychological Medicine, 2021, 51(13): 2168-2177. 

[6] SUN H L, BAI W, LI X H, et al. Schizophrenia and Inflammation Research: A Bibliometric Analysis[J/OL]. Frontiers in Immunology, 2022, 13: 907851. 

[7] REILLY T J, SAGNAY DE LA BASTIDA V C, JOYCE D W, et al. Exacerbation of Psychosis During the Perimenstrual Phase of the Menstrual Cycle: Systematic Review and Meta-analysis[J/OL]. Schizophrenia Bulletin, 2020, 46(1): 78-90. 

[8] GURVICH C, GAVRILIDIS E, WORSLEY R, et al. Menstrual cycle irregularity and menopause status influence cognition in women with schizophrenia[J/OL]. Psychoneuroendocrinology, 2018, 96: 173-178. 

[9] RUDNICKA E, SUCHTA K, GRYMOWICZ M, et al. Chronic Low Grade Inflammation in Pathogenesis of PCOS[J/OL]. International Journal of Molecular Sciences, 2021, 22(7): 3789. 

[10] JOHAM A E, NORMAN R J, STENER-VICTORIN E, et al. Polycystic ovary syndrome[J/OL]. The Lancet Diabetes & Endocrinology, 2022, 10(9): 668-680. 

[11] DOKRAS A, STENER-VICTORIN E, YILDIZ B O, et al. Androgen Excess- Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome[J/OL]. Fertility and Sterility, 2018, 109(5): 888-899. 

[12] WANG Y, NI Z, LI K. The prevalence of anxiety and depression of different severity in women with polycystic ovary syndrome: a meta-analysis[J/OL]. Gynecological Endocrinology, 2021, 37(12): 1072-1078. 

[13] DE SILVA V, SENANAYAKE A, RATNATUNGA S S, et al. Polycystic ovarian syndrome in patients with schizophrenia treated with atypical anti-psychotics: A case control study[J/OL]. European Psychiatry, 2017, 41(S1): S751-S751. 

[14] BIAŁOŃ M, WĄSIK A. Advantages and Limitations of Animal Schizophrenia Models[J/OL]. International Journal of Molecular Sciences, 2022, 23(11): 5968. 

[15] CHEN S F, YANG Y C, HSU C Y, et al. Risk of schizophrenia in patients with polycystic ovary syndrome: a nationwide population-based cohort study from Taiwan[J/OL]. Journal of Psychosomatic Obstetrics and Gynaecology, 2021, 42(4): 272-278. 

[16] ELLEUCH O, ZOUARI L, SMAOUI N, et al. Clinical determinants of social media use in patients with schizophrenia and schizo-affective disorder[J/OL]. European Psychiatry, 2022, 65(S1): S785-S785. 

[17] DAIRAGHI L, CONSTANTIN S, OH A, et al. The Dopamine D4 Receptor Regulates Gonadotropin-Releasing Hormone Neuron Excitability in Male Mice[J/OL]. eneuro, 2022, 9(2): ENEURO.0461-21.2022. 

[18] GANESH C B. The stress – Reproductive axis in fish: The involvement of functional neuroanatomical systems in the brain[J/OL]. Journal of Chemical Neuroanatomy, 2021, 112: 101904. 

[19] JAVAID S, AHMED U, LONE K P, et al. Plasma dopamine levels in Polycystic Ovary Syndrome women[J]. Pakistan Journal of Physiology, 2019, 15(3): 49-52.

[20] XU H, YANG F. The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia[J/OL]. Translational Psychiatry, 2022, 12(1): 464. 

[21] HOGARTH S, JAEHNE E J, XU X, et al. Interaction of Brain-Derived Neurotrophic Factor with the Effects of Chronic Methamphetamine on Prepulse Inhibition in Mice Is Independent of Dopamine D3 Receptors[J/OL]. Biomedicines, 2023, 11(8): 2290. 

[22] FRANKLE W G, HIMES M, MASON N S, et al. Prefrontal and Striatal Dopamine Release Are Inversely Correlated in Schizophrenia[J/OL]. Biological Psychiatry, 2022, 92(10): 791-799.

[23] CORRELL C U, ABI-DARGHAM A, HOWES O. Emerging Treatments in Schizophrenia[J/OL]. The Journal of Clinical Psychiatry, 2022, 83(1): 39683.

[24] FERNANDOIS D, VÁZQUEZ M J, BARROSO A, et al. Multi-Organ Increase in Norepinephrine Levels after Central Leptin Administration and Diet-Induced Obesity[J/OL]. International Journal of Molecular Sciences, 2023, 24(23): 16909. 

[25] ROBEVA R, ELENKOVA A, KIRILOV G, et al. Plasma-free metanephrines, nerve growth factor, and renalase significance in patients with PCOS[J/OL]. Endocrine, 2023, 81(3): 602-612. 

[26] RODRIGUES-AMORIM D, IGLESIAS-MARTÍNEZ-ALMEIDA M, RIVERA-BALTANÁS T, et al. The Role of the Second Extracellular Loop of Norepinephrine Transporter, Neurotrophin-3 and Tropomyosin Receptor Kinase C in T Cells: A Peripheral Biomarker in the Etiology of Schizophrenia[J/OL]. International Journal of Molecular Sciences, 2021, 22(16): 8499. 

[27] CARNAC T. Schizophrenia Hypothesis: Autonomic Nervous System Dysregulation of Fetal and Adult Immune Tolerance[J/OL]. Frontiers in Systems Neuroscience, 2022, 16: 844383. 

[28] SAVRANSKY A, CHIAPPELLI J, DU X, et al. Association of working memory and elevated overnight urinary norepinephrine in patients with schizophrenia[J/OL]. Journal of Psychiatric Research, 2021, 137: 89-95. 

[29] HU G, ZHU Y, DING S, et al. Role of gut microbiota in the 5-hydroxytryptamine signal transduction mechanism[J/OL]. Metabolism and Translational Medicine, 2023, 1[2024-08-05]. 

[30] BÓDIS J, SULYOK E, KŐSZEGI T, et al. Serum and follicular fluid levels of serotonin, kisspeptin, and brain-derived neurotrophic factor in patients undergoing in vitro fertilization: an observational study: Neurohormones in patients receiving IVF[J/OL]. Journal of International Medical Research, 2020, 48(4): 0300060519879330. 

[31] Ting Dong, Xiaoqin Yin, Yan Lin, et al. Effect of decreased 5-hydroxytryptamine synthesis during puberty development on the onset of puberty in female rats [J/OL]. Journal of Shanghai Jiaotong University(Medical Science), 2022, 42(3): 307. 

[32] CONIO B, MARTINO M, MAGIONCALDA P, et al. Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders[J/OL]. Molecular Psychiatry, 2020, 25(1): 82-93. 

[33] CARDINALE V, LEPORE E, BASCIANI S, et al. Positive Effects of α-Lactalbumin in the Management of Symptoms of Polycystic Ovary Syndrome[J/OL]. Nutrients, 2022, 14(15): 3220. 

[34] LANG X, XUE M, ZANG X, et al. Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study [J/OL]. Journal of Translational Medicine, 2023, 21(1): 1-9. 

[35] TSAPAKIS E M, DIAKAKI K, MILIARAS A, et al. Novel Compounds in the Treatment of Schizophrenia-A Selective Review[J/OL]. Brain Sciences, 2023, 13(8): 1193. 

[36] Quanchao Sun, Lijun Liu, Hongrui Gao. To analyze the "seesaw" correlation between neurotransmitters in patients with schizophrenia [J/OL]. Psychological Monthly, 2023, 18(14): 186-188. 

[37] Chao Han. To investigate the correlation and clinical significance of changes in serum neuro-related factors and 5-HT levels with PANSS scores in patients with schizophrenia [J/OL]. The Journal of Medical Theory and Practice, 2023, 36(6): 1008-1010. 

[38] KIM J H, SON Y D, KIM H K, et al. Association Between Lack of Insight and Prefrontal Serotonin Transporter Availability in Antipsychotic-Free Patients with Schizophrenia: A High-Resolution PET Study with [11C]DASB[J/OL]. Neuropsychiatric Disease and Treatment, 2021, 17: 3195-3203. 

[39] MCCARTNEY C R, CAMPBELL R E, MARSHALL J C, et al. The role of gonadotropin-releasing hormone neurons in polycystic ovary syndrome[J/OL]. Journal of Neuroendocrinology, 2022, 34(5): e13093. 

[40] FISH K N, ROCCO B R, DEDIONISIO A M, et al. Altered Parvalbumin Basket Cell Terminals in the Cortical Visuospatial Working Memory Network in Schizophrenia[J/OL]. Biological Psychiatry, 2021, 90(1): 47-57. 

[41] SAWAHATA M, ASANO H, NAGAI T, et al. Microinjection of Reelin into the mPFC prevents MK-801-induced recognition memory impairment in mice[J/OL]. Pharmacological Research, 2021, 173: 105832. 

[42] LINARES R, ACUÑA X N, ROSAS G, et al. Participation of the Cholinergic System in the Development of Polycystic Ovary Syndrome[J/OL]. Molecules, 2021, 26(18): 5506. 

[43] EICKHOFF S, FRANZEN L, KORDA A, et al. The Basal Forebrain Cholinergic Nuclei and Their Relevance to Schizophrenia and Other Psychotic Disorders[J/OL]. Frontiers in Psychiatry, 2022, 13: 909961. 

[44] URBAN-KOWALCZYK M, KOTLICKA-ANTCZAK M, STRZELECKI D, et al. The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia [J/OL]. Neuropsychiatric Disease and Treatment, 2021, 17: 503-512. 

[45] URBAN-KOWALCZYK M, KOTLICKA-ANTCZAK M, STRZELECKI D, et al. The Relationship Between Course of Illness and β-Endorphin Plasma Levels in Patients with Schizophrenia[J/OL]. Neuropsychiatric Disease and Treatment, 2019, 15: 3609-3614. 

[46] FENG J, WANG J, ZHANG Y, et al. The Efficacy of Complementary and Alternative Medicine in the Treatment of Female Infertility[J/OL]. Evidence-Based Complementary and Alternative Medicine, 2021, 2021: e6634309. 

[47] KIAŁKA M, MILEWICZ T, SPAŁKOWSKA M, et al. β-endorphins Plasma Level is Higher in Lean Polycystic Ovary Syndrome (PCOS) Women[J/OL]. Experimental and Clinical Endocrinology & Diabetes, 2016, 124(1): 55-60.